Veracyte (VCYT) Expected to Announce Quarterly Earnings on Wednesday

Veracyte (NASDAQ:VCYT) will likely be posting its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.41 per share and revenue of $135.7860 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Veracyte Stock Performance

Shares of VCYT opened at $36.03 on Wednesday. Veracyte has a 52 week low of $22.61 and a 52 week high of $50.71. The firm’s 50-day simple moving average is $40.87 and its 200 day simple moving average is $37.43. The firm has a market cap of $2.85 billion, a P/E ratio of 94.82 and a beta of 1.91.

Insider Activity at Veracyte

In related news, CFO Rebecca Chambers sold 13,278 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $46.84, for a total transaction of $621,941.52. Following the completion of the sale, the chief financial officer owned 109,496 shares in the company, valued at approximately $5,128,792.64. This trade represents a 10.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Annie Mcguire sold 10,739 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $43.13, for a total transaction of $463,173.07. Following the transaction, the senior vice president directly owned 67,760 shares of the company’s stock, valued at $2,922,488.80. This represents a 13.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 68,299 shares of company stock worth $3,102,756. 1.40% of the stock is owned by company insiders.

Institutional Trading of Veracyte

A number of large investors have recently bought and sold shares of VCYT. Guggenheim Capital LLC lifted its position in shares of Veracyte by 49.5% during the 4th quarter. Guggenheim Capital LLC now owns 40,423 shares of the biotechnology company’s stock valued at $1,702,000 after buying an additional 13,382 shares during the last quarter. Brown Capital Management LLC bought a new stake in Veracyte in the 4th quarter valued at about $4,806,000. AQR Capital Management LLC lifted its holdings in Veracyte by 3.9% during the fourth quarter. AQR Capital Management LLC now owns 28,293 shares of the biotechnology company’s stock valued at $1,191,000 after purchasing an additional 1,071 shares during the last quarter. EFG International AG purchased a new stake in Veracyte during the fourth quarter valued at about $5,603,000. Finally, Lazard Asset Management LLC boosted its position in Veracyte by 10.0% during the fourth quarter. Lazard Asset Management LLC now owns 42,484 shares of the biotechnology company’s stock worth $1,789,000 after purchasing an additional 3,856 shares during the period.

Analyst Upgrades and Downgrades

VCYT has been the subject of a number of recent analyst reports. UBS Group reiterated a “buy” rating on shares of Veracyte in a research report on Monday, January 12th. Zacks Research raised shares of Veracyte from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 11th. Needham & Company LLC boosted their price target on Veracyte from $41.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Veracyte in a report on Monday, December 29th. Finally, Morgan Stanley raised their price target on shares of Veracyte from $40.00 to $48.00 and gave the stock an “underweight” rating in a report on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Veracyte presently has an average rating of “Moderate Buy” and a consensus target price of $46.14.

About Veracyte

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.